Four leading companies prognosticate coming successes of new technology approaches to better tumor-infiltrating lymphocyte activities
Tumor-infiltrating lymphocytes (TILs) are a grouping of mostly T cells that enter tumors and elicit an initial immune response. But as Jason Bock, PhD, co-founder and CEO of CTMC, explains, “These cells have been fighting against the tumor, but the balance has shifted, and the tumor has gained the upper hand.” He notes that traditional TIL therapy typically involves extracting the TILs from each patient’s tumor, expanding and reinvigorating them, and then reinfusing them into the patient. In recent interviews with GEN, four leading companies shared their insights about the state of TIL therapy in 2025.
Access article: GEN News